Literature DB >> 22318013

Sangamo's lead zinc-finger therapy flops in diabetic neuropathy.

Michael Eisenstein.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22318013     DOI： 10.1038/nbt0212-121a

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN： 1087-0156            Impact factor:   54.908


× No keyword cloud information.
  4 in total

1.  Move over ZFNs.

Authors: 
Journal:  Nat Biotechnol       Date:  2011-08-05       Impact factor: 54.908

2.  Regulation of an endogenous locus using a panel of designed zinc finger proteins targeted to accessible chromatin regions. Activation of vascular endothelial growth factor A.

Authors:  P Q Liu; E J Rebar; L Zhang; Q Liu; A C Jamieson; Y Liang; H Qi; P X Li; B Chen; M C Mendel; X Zhong; Y L Lee; S P Eisenberg; S K Spratt; C C Case; A P Wolffe
Journal:  J Biol Chem       Date:  2001-01-05       Impact factor: 5.157

3.  Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleases.

Authors:  Elena E Perez; Jianbin Wang; Jeffrey C Miller; Yann Jouvenot; Kenneth A Kim; Olga Liu; Nathaniel Wang; Gary Lee; Victor V Bartsevich; Ya-Li Lee; Dmitry Y Guschin; Igor Rupniewski; Adam J Waite; Carmine Carpenito; Richard G Carroll; Jordan S Orange; Fyodor D Urnov; Edward J Rebar; Dale Ando; Philip D Gregory; James L Riley; Michael C Holmes; Carl H June
Journal:  Nat Biotechnol       Date:  2008-06-29       Impact factor: 54.908

4.  In vivo genome editing restores haemostasis in a mouse model of haemophilia.

Authors:  Hojun Li; Virginia Haurigot; Yannick Doyon; Tianjian Li; Sunnie Y Wong; Anand S Bhagwat; Nirav Malani; Xavier M Anguela; Rajiv Sharma; Lacramiora Ivanciu; Samuel L Murphy; Jonathan D Finn; Fayaz R Khazi; Shangzhen Zhou; David E Paschon; Edward J Rebar; Frederic D Bushman; Philip D Gregory; Michael C Holmes; Katherine A High
Journal:  Nature       Date:  2011-06-26       Impact factor: 49.962
  4 in total
  8 in total

1.  Alnylam's RNAi therapy targets amyloid disease.

Authors:  Ken Garber
Journal:  Nat Biotechnol       Date:  2015-06       Impact factor: 54.908

2.  Alnylam launches era of RNAi drugs.

Authors:  Ken Garber
Journal:  Nat Biotechnol       Date:  2018-09-06       Impact factor: 54.908

Review 3.  The past and presence of gene targeting: from chemicals and DNA via proteins to RNA.

Authors:  T M Geel; M H J Ruiters; R H Cool; L Halby; D C Voshart; L Andrade Ruiz; K E Niezen-Koning; P B Arimondo; M G Rots
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2018-06-05       Impact factor: 6.237

4.  Functional validation of putative tumor suppressor gene C13ORF18 in cervical cancer by Artificial Transcription Factors.

Authors:  Christian Huisman; G Bea A Wisman; Hinke G Kazemier; Marcel A T M van Vugt; Ate G J van der Zee; Ed Schuuring; Marianne G Rots
Journal:  Mol Oncol       Date:  2013-03-05       Impact factor: 6.603

5.  Engineering synthetic TALE and CRISPR/Cas9 transcription factors for regulating gene expression.

Authors:  Ami M Kabadi; Charles A Gersbach
Journal:  Methods       Date:  2014-07-08       Impact factor: 3.608

Review 6.  Tuning up Transcription Factors for Therapy.

Authors:  Attila Becskei
Journal:  Molecules       Date:  2020-04-20       Impact factor: 4.411

Review 7.  Epigenetic Editing: targeted rewriting of epigenetic marks to modulate expression of selected target genes.

Authors:  Marloes L de Groote; Pernette J Verschure; Marianne G Rots
Journal:  Nucleic Acids Res       Date:  2012-09-21       Impact factor: 16.971

Review 8.  The prospect of molecular therapy for Angelman syndrome and other monogenic neurologic disorders.

Authors:  Barbara J Bailus; David J Segal
Journal:  BMC Neurosci       Date:  2014-06-19       Impact factor: 3.288
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.